

MATRIX[®]

(altrenogest)

For synchronization of estrus in sexually mature gilts that have had at least one estrous cycle.

Advantages

- Treatment with altrenogest solution 0.22% results in estrus (standing heat) four to nine days after completion of the 14-day treatment period.
- Enhances profitability by creating a predictable breeding timetable for gilts, reducing heat checking and eliminating weekend breeding and farrowing.¹
- Improves operating efficiency due to unparalleled control of estrus synchronization.
- Convenient handling system

Do not use in gilts having a previous or current history of uterine inflammation (i.e., acute, subacute or chronic endometritis). Underfeeding of MATRIX[®] may lead to the occurrence of cystic follicles. Gilts must not be slaughtered for human consumption for 21 days after the last treatment.

For complete safety information on the use/handling of this product, see accompanying product package insert.

REFERENCES

1. Flowers, William L. "Dose confirmation study in sexually mature gilts orally administered altrenogest (Regu-Mate solution 0.22%) to suppress and synchronize estrus." Summary and statistical analyses report. Sponsor study number: HRV 97-0014. June 29, 1999. Intervet/Schering-Plough Animal Health, Millsboro, DE.



Code: 003488
Size: 1,000 mL



MATRIX[®] (altrenogest)

USE:

For synchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with altrenogest solution 0.22% results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.

CAUTION:

Federal law prohibits extra-label use of this drug to enhance food and/or fiber production in animals. **Do Not Use:** In gilts having a previous or current history of uterine inflammation (i.e., acute, subacute or chronic endometritis).

WARNINGS:

User/Handler Safety: Keep this and all medication out of the reach of children.

Avoid skin contact. Wear vinyl, polyethylene, neoprene, butyl or nitrile protective gloves when handling this product. Pregnant women or women who suspect they are pregnant should not handle MATRIX[®] (altrenogest solution 0.22%). Women of child-bearing age should exercise extreme caution when handling this product. Accidental absorption could lead to a disruption of the menstrual cycle or prolongation of pregnancy. Wash off accidental spillage on the skin immediately with soap and water.

People who should not handle this product:

1. Women who are or suspect they are pregnant.
2. Anyone with thrombophlebitis or thromboembolic disorders or with a history of these events.
3. Anyone with cerebral-vascular or coronary-artery disease.
4. Women with known or suspected carcinoma of the breast.
5. People with known or suspected estrogen-dependent neoplasia.
6. Women with undiagnosed vaginal bleeding.
7. People with benign or malignant tumors which developed during the use of oral contraceptives or other estrogen-containing products.
8. Anyone with liver dysfunction or disease.

ACCIDENTAL EXPOSURE:

Altrenogest is readily absorbed from contact with the skin. In addition, this oil based product can penetrate porous gloves. Altrenogest should not penetrate intact vinyl, polyethylene, neoprene, butyl or nitrile protective gloves; however, if there is leakage (i.e., pinhole, spillage, etc.) the contaminated area covered by such occlusive materials may have increased absorption.

The following measures are recommended in case of accidental exposure.

Skin Exposure: Wash immediately with soap and water.

Eye Exposure: Immediately flush with plenty of water for 15 minutes. Get medical attention.

If Swallowed: Do not induce vomiting. MATRIX[®] (altrenogest solution 0.22%) contains an oil. Call a physician. Vomiting should be supervised by a physician because of possible pulmonary damage via aspiration of the oil base. If possible, bring the container and labeling to the physician.

EFFECTS OF OVEREXPOSURE:

There has been no human use of this specific product. The information contained in this section is extrapolated from data available on other products of the same pharmacological class that have been used in humans. Effects anticipated are due to the progestational activity of altrenogest. Acute effects after a single exposure are possible; however, continued daily exposure has the potential for more untoward effects such as disruption of the menstrual cycle, uterine or abdominal cramping, increased or decreased uterine bleeding, prolongation of pregnancy and headaches. The oil base may also cause complications if swallowed. In addition, the list of people who should not handle this product is based upon the known effects of progestins used in humans on a chronic basis.

HUMAN FOOD SAFETY: GILTS MUST NOT BE SLAUGHTERED FOR HUMAN CONSUMPTION FOR 21 DAYS AFTER THE LAST TREATMENT.

ENVIRONMENTAL SAFETY:

Place empty drug containers and used syringes, protective gloves or other articles that come in contact with this product in a leak-resistant container for disposal in accordance with applicable Federal, state and local regulations.

ADVERSE REACTIONS AND POTENTIAL SAFETY HAZARDS:

Underfeeding of MATRIX[®] may lead to the occurrence of cystic follicles.

WHEN USING THIS PRODUCT:

A small percentage (less than 5%) of treated gilts may exhibit estrus (standing heat) during the 14-day treatment period. Gilts nearing estrus at the start of the 14-day treatment period may express estrus early in that period.

DOSAGE AND DIRECTIONS:

While wearing protective gloves, remove shipping cap and seal; replace with enclosed plastic dispensing cap. Remove cover from bottle dispensing tip and connect luer lock syringe (without needle). Draw out appropriate volume of MATRIX[®] solution. (Note: Do not remove syringe while bottle is inverted as spillage may result.) Detach syringe and replace cover on bottle dispensing tip to prevent leakage. Administer 6.8 mL (15 mg altrenogest) per gilt once daily for 14 consecutive days. Treat gilts on an individual animal basis by top-dressing MATRIX[®] on a portion of each gilt's daily feed allowance. To produce the desired synchronization of estrus in a group of gilts, treat all of the gilts daily for the same 14-day period. Excessive use of a syringe may cause the syringe to stick; therefore, replace syringe as necessary.

OTHER INFORMATION:

Storage: Store at or below room temperature, 77°F (25°C). Close tightly.

QUESTIONS? COMMENTS?

- To report a suspected adverse reaction, call **1-800-548-2423**.
- To obtain product information, including material safety data sheet (MSDS), call 1-800-441-8272.

Manufactured by: DPT Laboratories, Inc., San Antonio, TX 78215
Distributed by: Merck Animal Health
NADA 141-222, Approved by FDA

*U.S. patent Registration Nos. 5,468,485 and 5,378,744

READ AND FOLLOW LABEL DIRECTIONS

U.S. Veterinary License No. 165A

FOR VETERINARY USE ONLY

556 Morris Avenue • Summit, NJ 07901 • merck-animal-health-usa.com • 800-521-5767
Copyright © 2013 Intervet Inc., a subsidiary of Merck & Co., Inc. All rights reserved.
SW-MX-19923 (01-13)

